BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32184664)

  • 21. The stem cell factor SALL4 is an essential transcriptional regulator in mixed lineage leukemia-rearranged leukemogenesis.
    Yang L; Liu L; Gao H; Pinnamaneni JP; Sanagasetti D; Singh VP; Wang K; Mathison M; Zhang Q; Chen F; Mo Q; Rosengart T; Yang J
    J Hematol Oncol; 2017 Oct; 10(1):159. PubMed ID: 28974232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. mRNA overexpression of
    Azizi Z; Rahgozar S; Moafi A; Dabaghi M; Nadimi M
    Biomed Rep; 2015 May; 3(3):371-374. PubMed ID: 26137238
    [No Abstract]   [Full Text] [Related]  

  • 23. Overexpression of SORCIN is a Prognostic Biomarker for Multidrug-Resistant Pediatric Acute Lymphoblastic Leukemia and Correlates with Upregulated MDR1/P-gp.
    Dabaghi M; Rahgozar S; Moshtaghian J; Moafi A; Abedi M; Pourabutaleb E
    Genet Test Mol Biomarkers; 2016 Sep; 20(9):516-21. PubMed ID: 27382961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia.
    Steinbach D; Gillet JP; Sauerbrey A; Gruhn B; Dawczynski K; Bertholet V; de Longueville F; Zintl F; Remacle J; Efferth T
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4357-63. PubMed ID: 16857811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A New Indole Derivative Decreased SALL4 Gene Expression in Acute Promyelocytic Leukemia Cell Line (NB4).
    Sheikhrezaei Z; Heydari P; Farsinezhad A; Fatemi A; Khanamani Falahati-Pour S; Darakhshan S; Noroozi Karimabad M; Darekordi A; Khorramdelazad H; Hassanshahi G
    Iran Biomed J; 2018 Mar; 22(2):99-106. PubMed ID: 28800701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone lysine-specific demethylase 1 (LSD1) protein is involved in Sal-like protein 4 (SALL4)-mediated transcriptional repression in hematopoietic stem cells.
    Liu L; Souto J; Liao W; Jiang Y; Li Y; Nishinakamura R; Huang S; Rosengart T; Yang VW; Schuster M; Ma Y; Yang J
    J Biol Chem; 2013 Nov; 288(48):34719-28. PubMed ID: 24163373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stemness state regulators SALL4 and SOX2 are involved in progression and invasiveness of esophageal squamous cell carcinoma.
    Forghanifard MM; Ardalan Khales S; Javdani-Mallak A; Rad A; Farshchian M; Abbaszadegan MR
    Med Oncol; 2014 Apr; 31(4):922. PubMed ID: 24659265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Spalt-like transcription factor 4 expression in oral epithelial dysplasia and oral squamous cell carcinoma: An immunohistochemical appraisal.
    Kulkarni S; Solomon M; Chandrashekar C; Shetty N; Carnelio S
    J Carcinog; 2020; 19():12. PubMed ID: 33679242
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Developmental expression of the pluripotency factor sal-like protein 4 in the monkey, human and mouse testis: restriction to premeiotic germ cells.
    Eildermann K; Aeckerle N; Debowski K; Godmann M; Christiansen H; Heistermann M; Schweyer S; Bergmann M; Kliesch S; Gromoll J; Ehmcke J; Schlatt S; Behr R
    Cells Tissues Organs; 2012; 196(3):206-20. PubMed ID: 22572102
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Use of allogeneic hematopoietic stem-cell transplantation based on minimal residual disease response improves outcomes for children with relapsed acute lymphoblastic leukemia in the intermediate-risk group.
    Eckert C; Henze G; Seeger K; Hagedorn N; Mann G; Panzer-Grümayer R; Peters C; Klingebiel T; Borkhardt A; Schrappe M; Schrauder A; Escherich G; Sramkova L; Niggli F; Hitzler J; von Stackelberg A
    J Clin Oncol; 2013 Jul; 31(21):2736-42. PubMed ID: 23775972
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4.
    Yang J; Aguila JR; Alipio Z; Lai R; Fink LM; Ma Y
    J Hematol Oncol; 2011 Sep; 4():38. PubMed ID: 21943195
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sal-like protein 4 (SALL4), a stem cell biomarker in liver cancers.
    Oikawa T; Kamiya A; Zeniya M; Chikada H; Hyuck AD; Yamazaki Y; Wauthier E; Tajiri H; Miller LD; Wang XW; Reid LM; Nakauchi H
    Hepatology; 2013 Apr; 57(4):1469-83. PubMed ID: 23175232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Comparison of prognostic significance between multiparameter flow cytometry and real-time quantitative polymerase chain reaction in the detection of minimal residual disease of Philadelphia chromosome-positive acute B lymphocytic leukemia before allogeneic hematopoietic stem cell transplantation].
    Wang XY; Chang YJ; Liu YR; Qin YQ; Xu LP; Wang Y; Zhang XH; Yan CH; Sun YQ; Huang XJ; Zhao XS
    Zhonghua Xue Ye Xue Za Zhi; 2021 Feb; 42(2):116-123. PubMed ID: 33858041
    [No Abstract]   [Full Text] [Related]  

  • 35. Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations.
    Misawa K; Misawa Y; Mima M; Yamada S; Imai A; Mochizuki D; Nakagawa T; Kurokawa T; Endo S; Kawasaki H; Brenner JC; Mineta H
    Cell Oncol (Dordr); 2020 Aug; 43(4):631-641. PubMed ID: 32240499
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Knockdown of SALL4 overcomes cisplatin-resistance through AKT/mTOR signaling in lung cancer cells.
    Jiang G; Liu CT
    Int J Clin Exp Pathol; 2018; 11(2):634-641. PubMed ID: 31938149
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Minimal residual disease monitoring in adult T-cell acute lymphoblastic leukemia: a molecular based approach using T-cell receptor G and D gene rearrangements.
    Gameiro P; Mortuza FY; Hoffbrand AV; Foroni L
    Haematologica; 2002 Nov; 87(11):1126-34. PubMed ID: 12414341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. SALL4: an emerging cancer biomarker and target.
    Zhang X; Yuan X; Zhu W; Qian H; Xu W
    Cancer Lett; 2015 Feb; 357(1):55-62. PubMed ID: 25444934
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
    Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative detection of the human cervical cancer oncogene for monitoring the minimal residual disease in acute leukemia.
    Qiao SK; Guo XN; Ren JH; Zhang JN; Wang Y
    Exp Biol Med (Maywood); 2015 Jan; 240(1):128-34. PubMed ID: 25034723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.